Vertex Pharmaceuticals (NASDAQ:VRTX) Stock: Insider Charles Wagner, Jr. Sells 15,286 Shares

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Get Free Report) EVP Charles Wagner, Jr. sold 15,286 shares of the business's stock in a transaction dated Thursday, November 12th. The shares were sold at an average price of $547.87, for a total value of $8,374,740.82. Following the completion of the transaction, the executive vice president directly owned 31,764 shares of the company's stock, valued at approximately $17,402,542.68. This trade represents a 32.49% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Vertex Pharmaceuticals Stock Down 0.2%

Shares of VRTX opened at $537.79 on Tuesday. Vertex Pharmaceuticals Incorporated has a 52 week low of $412.27 and a 52 week high of $568.67. The company has a quick ratio of 1.89, a current ratio of 2.34 and a debt-to-equity ratio of 0.17. The company has a market capitalization of $136.35 billion, a price-to-earnings ratio of 34.61, a PEG ratio of 2.87 and a beta of 0.28. The stock's 50-day moving average price is $522.20 and its 200-day moving average price is $484.14.




Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last posted its earnings results on Monday, November 2nd. The pharmaceutical company reported $4.76 EPS for the quarter, missing the consensus estimate of $4.82 by ($0.06). The company had revenue of $3.44 billion for the quarter, compared to analyst estimates of $3.42 billion. Vertex Pharmaceuticals had a return on equity of 21.98% and a net margin of 30.70%. The firm's revenue was up 11.8% on a year-over-year basis. During the same period last year, the business earned $4.80 earnings per share. On average, sell-side analysts predict that Vertex Pharmaceuticals Incorporated will post 16.10 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on VRTX shares. TD Cowen upped their price objective on Vertex Pharmaceuticals from $550.00 to $575.00 and gave the stock a "buy" rating in a research report on Tuesday, November 3rd. Weiss Ratings cut shares of Vertex Pharmaceuticals from a "buy (b)" rating to a "buy (b-)" rating in a research note on Monday, November 9th. Rothschild & Co Redburn lifted their target price on shares of Vertex Pharmaceuticals from $570.00 to $580.00 and gave the company a "buy" rating in a report on Wednesday, August 5th. Royal Bank Of Canada boosted their target price on shares of Vertex Pharmaceuticals from $576.00 to $600.00 and gave the company an "outperform" rating in a research note on Tuesday, November 3rd. Finally, Wells Fargo & Company boosted their target price on shares of Vertex Pharmaceuticals from $550.00 to $650.00 and gave the company an "overweight" rating in a research note on Tuesday, November 3rd. One equities research analyst has rated the stock with a Strong Buy rating, twenty-five have given a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $596.44.

View Our Latest Stock Report on VRTX

Institutional Investors Weigh In On Vertex Pharmaceuticals

A number of institutional investors have recently modified their holdings of the business. Summit Global Investments purchased a new stake in shares of Vertex Pharmaceuticals in the second quarter valued at approximately $3,568,000. Danica Pension Livsforsikringsaktieselskab acquired a new stake in shares of Vertex Pharmaceuticals in the second quarter valued at approximately $13,823,000. UNIVEST FINANCIAL Corp purchased a new position in Vertex Pharmaceuticals during the second quarter worth approximately $4,495,000. State Street Corp lifted its position in Vertex Pharmaceuticals by 1.2% during the second quarter. State Street Corp now owns 11,871,459 shares of the pharmaceutical company's stock worth $5,896,910,000 after buying an additional 141,320 shares in the last quarter. Finally, Meeder Advisory Services Inc. purchased a new position in Vertex Pharmaceuticals during the second quarter worth approximately $3,187,000. 90.96% of the stock is currently owned by institutional investors and hedge funds.

Vertex Pharmaceuticals Company Profile

(Get Free Report)

Vertex Pharmaceuticals is a biotechnology company headquartered in Boston, Massachusetts. Founded in 1989, it develops medicines for serious diseases, with a long-standing focus on cystic fibrosis (CF). Vertex's CF treatments include medicines that target the underlying protein defect, such as Trikafta/Kaftrio, Alyftrek, Kalydeco, Orkambi and Symdeko/Symkevi. The company also markets Journavx, a non-opioid medicine for acute pain, and partnered with CRISPR Therapeutics to develop Casgevy, a gene-editing treatment for sickle cell disease and transfusion-dependent beta thalassemia.

Recommended Stories

Insider Buying and Selling by Quarter for Vertex Pharmaceuticals (NASDAQ:VRTX)

This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].

Insider Buying or Selling at Vertex Pharmaceuticals?
Sign-up to receive InsiderTrades.com's daily insider buying and selling report for Vertex Pharmaceuticals and related companies.
Free Insider Buying and Selling Newsletter
Enter your email address below to receive InsiderTrades.com's daily insider buying and selling report.
From Our Partners

Most Read This Month

Recent Articles